Products
| CATALOG NO | PRODUCT NAME | CAS | PURITY | STRUCTURE |
|---|---|---|---|---|
| 18381 | JPH203 HCl ( Nanvuranlat ) | 1597402-27-1 | ≧98.0% |  |
| JPH203, also known as KYT-0353, is a potent and selective LAT1 selective ( L-type ami | ||||
| 1811211 | Anlotinib HCl ( AL-3818 ) | 1360460-82-7 | ≧98.0% |  |
| Anlotinib is a novel oral tyrosine kinase inhibitor (TKI) targeting c-kit, platelet-d | ||||
| 21257 | Difelikefalin | 1024828-77-0 | ≧98.0% |  |
| Difelikefalin HCl is in stock.Difelikefalin, also known CR-845; MR-13A-9; MR-13A9, is | ||||
| 20259 | Elinzanetant ( NT-814 ) | 929046-33-3 | ≧98.0% |  |
| Elinzanetant, previously known as NT-814 (45), is a dual NK1,3R antagonist and theref | ||||
| 20266 | Linzagolix | 935283-04-8 | ≧98.0% |  |
| Linzagolix is a novel, orally administered GnRH receptor antagonist that potentially | ||||
| 21075 | 1-cyanocyclohexyl 4-methylbenzenesulfonate | 90775-01-2 | ≧98.0% |  |
| 1-cyanocyclohexyl 4-methylbenzenesulfonate (CAS 90775-01-2 ) is an important building | ||||
| 20306 | SRI-37330 HCl | 2322245-49-6 | ≧98.0% |  |
| SRI-37330 hydrochloride is a novel inhibitor of TXNIP expression,and dose-dependently | ||||
| 18435 | Ritlecitinib ( PF-06651600 ) | 1792180-81-4 | ≧98.0% | _1792180-81-4.png) |
| Ritlecitinib ( PF-06651600 ) is a potent and selective JAK3 inhibitor. PF-06651600, a | ||||
| 2091204 | 5-hydroxy-2,4-dimethylpyrimidine | 412003-95-3 | ≧96.0% |  |
| 2,4-dimethylpyrimidin-5-ol is a key intermidiate ofLemborexant. Kg scale may be provi | ||||
| 16122809 | Elacestrant | 722533-56-4 | ≧98.0% |  |
| Elacestrant, also known as RAD1901, is an orally available, selective estrogen recept | ||||
| 20265 | Daridorexant ( ACT541468 ) | 1505484-82-1 | ≧98.0% | _1505484-82-1.gif) |
| Daridorexant is a dual orexin receptor antagonist (DORA) designed and developed for t | ||||
| 20273 | Delgocitinib（JTE-052） | 1263774-59-9 | ≧98.0% |  |
| Delgocitinib, also known as LEO-124249 and JTE052, is a potent and selective JAK inhi | ||||